HCPLive

Top Medical News Today

Liberia Officially Declared Free of Ebola Transmission
The World Health Organization (WHO) announced on September 3 that Liberia is free of Ebola virus transmission in the human population – something that has not been the case since the first diagnosis was reported in West Africa in March 2014.
The Mediterranean DASH Intervention for Neurodegenerative Delay (MIND) diet may lower a person’s risk of developing Alzheimer’s disease, according to findings published in the journal Alzheimer’s & Dementia. The study authors believed this is true even if the diet is not meticulously followed.
Several large groups combined data to look at results of a study on heart failure patients to see whether age and gender affected treatment options prescribed by patients.
The first study of its kind examined joint replacement surgery in patients with osteoarthritis and confirmed an increased risk of cardiovascular complications.
A New Jersey pharma company has won a round in its fight to advertise a fish oil pill for a non-FDA approved use. Critics, writing in the NEJM say that puts the nation's drug safety monitoring at risk.
Fecal microbiota transplantation (FMT), already shown to be effective for Clostridium difficile treatment, has been found to eradicate two of the most common antibiotic-resistant hospital superbugs: vancomycin-resistant Enterococcus faecium (VRE) and multidrug-resistant Klebsiella pneumoniae.
The largest case series to date of outcomes in patients with herpetic meningoencephalits (HME) shows early diagnosis and treatment is critical if the damage is to be held in check. Rapid treatment is common in the US, but globally, a Turkish researcher found, delays of days or even a week are not uncommon.
A review article recently examined the evidence (or lack thereof) supporting the use of textiles, vitamin supplements, climatotherapy, probiotics, bleach baths, and other forms of complementary and alternative medicine for the treatment of atopic dermatitis.
While digoxin has been a popular medication in the past, particularly for patients with atrial fibrillation, a recent study looked at whether the medication was indeed beneficial for treatment when compared to placebo or no pharmaceutical therapy at all. Digoxin may be a popular treatment for some patients, but often doctors cannot look at just one condition when treating and have to consider multiple factors and issues.

Features

Resources for Your Patients

Click here for the latest hepatitis C news and updates for patients

Most Popular

Recent Published Journal

$vacMongoViewPlus$ $vAR$